Re: RVX-297 vs RVX-208 for autoimmune indications
in response to
by
posted on
Jan 09, 2019 02:49PM
..one would think with a successful BoM trial and thus the pending approval of 208 that the intrinsic value of RVX coupled with speculation of future drug approvals would catapult the share price into the statusphere!!,,,,and if not bought out in due course that the long term hold of these shares would be perhpas the smartest move of a shreholders investing career!,,jmo